Skip to main content
AMGEN INC logo

AMGEN INC — Investor Relations & Filings

Ticker · AMGN ISIN · US0311621009 LEI · 62QBXGPJ34PQ72Z12S66 US Manufacturing
Open in API
Filings indexed 1,984 across all filing types
Latest filing 2026-05-20 Declaration of Voting R…
Country US United States of America
Listing US AMGN

About AMGEN INC

https://www.amgen.com/

Amgen Inc. is a multinational biotechnology company focused on discovering, developing, manufacturing, and delivering innovative human therapeutics. As a pioneer in the field, the company utilizes advanced science and technology, including genetics and molecular engineering, to create biologic medicines from living cells. Amgen's portfolio and pipeline target serious illnesses with limited treatment options across key therapeutic areas, including oncology, cardiovascular disease, inflammation, bone health, and neuroscience. The company's mission is to translate scientific promise into therapies that restore health and improve the lives of patients worldwide.

Recent filings

Filing Released Lang Actions
8-K
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a Form 8-K filed under Item 5.07 “Submission of Matters to a Vote of Security Holders,” which provides the official vote counts for director elections, advisory votes, and other proposals at the Annual Meeting on May 19, 2026. This clearly matches the definition of Declaration of Voting Results & Voting Rights Announcements (DVA).
2026-05-20 English
8-K
Board/Management Information Classification · 92% confidence The document is a Form 8-K “Current Report” detailing the retirement of the company’s CFO and the appointment of a new Executive Vice President and Chief Financial Officer, including descriptions of their employment agreements and background. This constitutes an official announcement of changes in senior management, fitting the “Board/Management Information” category (MANG).
2026-05-19 English
10-Q
Interim / Quarterly Report Q1 2026
2026-05-01 English
8-K
Earnings Release Classification · 90% confidence The document is a Form 8-K “Current Report” under Item 2.02 announcing the company’s unaudited first quarter 2026 results via a press release. It furnishes an earnings press release as Exhibit 99.1. This constitutes an initial announcement of quarterly financial results rather than a full interim report or other filing. Therefore, it is classified as an Earnings Release (ER). Q1 2026
2026-04-30 English
Major Shareholding Notification 2026
Major Shareholding Notification
2026-04-29 English
8-K - AMGEN INC (0000318154) (Filer)
Board/Management Information Classification · 100% confidence The document is a Form 8-K filed with the SEC, which is a Current Report used to announce major events that shareholders should know about. The content specifically details the departure and retirement of a senior executive, David M. Reese, including redistribution of his responsibilities and retirement benefits. This matches the description of Board/Management Information filings, which announce changes in the company's board of directors or senior management. The document is not a full annual or quarterly report, nor is it an earnings release or proxy statement. It is not a regulatory filing of miscellaneous nature but a specific management change announcement. Therefore, the appropriate classification is MANG (Board/Management Information). The document length and detail support a high confidence score.
2026-04-22 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.